

1 RNA structure modulates Cas13 activity 2 and enables mismatch detection

3 Ofer Kimchi^{1,*}, Benjamin B. Larsen^{2,*}, Owen R. S. Dunkley², Aartjan J.W. te Velthuis², and
4 Cameron Myhrvold^{2,3,4,5 †}

5 ¹Lewis-Sigler Institute for Integrative Genomics, Princeton University, Princeton, New Jersey, 08544, USA

6 ²Department of Molecular Biology, Princeton University, Princeton, New Jersey, 08544, USA

7 ³Department of Chemical and Biological Engineering, Princeton University, Princeton, New Jersey, 08544, USA

8 ⁴Omenn-Darling Bioengineering Institute, Princeton University, Princeton, New Jersey, 08544, USA

9 ⁵Department of Chemistry, Princeton University, Princeton, New Jersey, 08544, USA

10 *These authors contributed equally

11 †Corresponding author: cmyhrvol@princeton.edu

12 Key words: Cas13, CRISPR, RNA detection, RNA structure, strand displacement

13 Abstract

14
15 The RNA-targeting CRISPR nuclease Cas13 has emerged as a powerful tool for applications
16 ranging from nucleic acid detection to transcriptome engineering and RNA imaging¹⁻⁶. Cas13 is
17 activated by the hybridization of a CRISPR RNA (crRNA) to a complementary single-stranded
18 RNA (ssRNA) protospacer in a target RNA^{1,7}. Though Cas13 is not activated by double-
19 stranded RNA (dsRNA) *in vitro*, it paradoxically demonstrates robust RNA targeting in
20 environments where the vast majority of RNAs are highly structured^{2,8}. Understanding Cas13's
21 mechanism of binding and activation will be key to improving its ability to detect and perturb
22 RNA; however, the mechanism by which Cas13 binds structured RNAs remains unknown⁹.
23 Here, we systematically probe the mechanism of LwaCas13a activation in response to RNA
24 structure perturbations using a massively multiplexed screen. We find that there are two distinct
25 sequence-independent modes by which secondary structure affects Cas13 activity: structure in
26 the protospacer region competes with the crRNA and can be disrupted via a strand-
27 displacement mechanism, while structure in the region 3' to the protospacer has an allosteric
28 inhibitory effect. We leverage the kinetic nature of the strand displacement process to improve
29 Cas13-based RNA detection, enhancing mismatch discrimination by up to 50-fold and enabling
30 sequence-agnostic mutation identification at low (<1%) allele frequencies. Our work sets a new
31 standard for CRISPR-based nucleic acid detection and will enable intelligent and secondary-
32 structure-guided target selection while also expanding the range of RNAs available for targeting
33 with Cas13.

34

35 Main text

36 The RNA-targeting CRISPR effector protein Cas13 holds tremendous promise for numerous
37 applications, such as RNA targeting, detection, editing, and imaging^{1–5,7,10}. Cas13 is activated by
38 the hybridization of a CRISPR RNA (crRNA) spacer sequence to a complementary region in a
39 target RNA (the protospacer)^{7,11}. Once activated, Cas13 cleaves both the target RNA (*cis*
40 cleavage) and other RNAs in solution (*trans* cleavage)^{2,3,7,9}. However, the biophysical process
41 by which the Cas13-crRNA complex binds to and is activated by a target RNA is poorly
42 understood.

43 Understanding the mechanism of Cas13 activation would solve several key challenges. First,
44 even with perfect complementarity between crRNA and protospacer, Cas13 activity levels can
45 vary by several orders of magnitude^{12–14}. While the specifics of the crRNA and target
46 sequences—including spacer length, nucleotide sequence, and crRNA/protospacer
47 mismatches—are known to affect Cas13 activity, much of this variation remains unaccounted
48 for^{12–14}. RNA secondary structure is an intriguing candidate to explain this variation, since unlike
49 the CRISPR effector proteins Cas9 and Cas12, Cas13 is believed to be incapable of unwinding
50 structured targets^{11,15}. Models including only sequence effects while excluding structural effects
51 have had success with a binary classification of active/inactive crRNAs, but have not been able
52 to solve the regression problem of quantitatively predicting Cas13 activity from the crRNA
53 sequence^{12,13,16}. Second, although Cas13 activation requires crRNA/protospacer
54 complementarity, Cas13 is frequently activated to a similar or even greater degree in the
55 presence of single mismatches^{17,18}. We hypothesized that these two poorly understood
56 characteristics of Cas13 could be addressed by studying the activation of Cas13 in more detail
57 using structured RNAs as a model system.

58 RNA molecules form intramolecular base pairs (secondary structures) that compete with
59 intermolecular RNA-RNA interactions. We sought to explore how this competition affects the
60 crRNA-target interactions underlying Cas13 activation. RNA secondary structure has long been
61 suspected to influence Cas13 activity due to its competition with the crRNA for target base
62 pairing, but this has been challenging to study in isolation, as primary sequence and secondary
63 structure are inextricably linked¹⁹. Abudayyeh & Gootenberg *et al.* showed a small but
64 significant negative correlation between secondary structure and Cas13a activity for crRNAs
65 targeting different regions of four genes in HEK293FT cells². By tiling the long non-coding RNA
66 Xist in HEK293T cells, Bandaru *et al.* showed that crRNAs are typically more active when
67 targeting single-stranded regions than double-stranded regions²⁰. By examining different
68 regions of natural RNAs, prior studies have been unable to distinguish between effects on
69 Cas13 caused by changes to target structure, and those caused by changes to target
70 sequence. Thus, the degree to which the RNA structure affects crRNA-target binding and
71 Cas13 activity remains unclear.

72 RNA structure reduces LwaCas13a activity

73 To isolate the effect of RNA structure on Cas13 activity, we designed an ssRNA protospacer

74 sequence to which we could add variable amounts of secondary structure by either
75 intramolecular extension of an RNA hairpin, or by adding external complementary RNA or DNA
76 oligonucleotides of different lengths, termed “occluders” (Fig. 1A). We designed the protospacer
77 to reflect viral sequence diversity and to have minimal secondary structure in the absence of
78 these modifications (see Methods). We tested the ability of these structured protospacers to
79 activate LwaCas13a using cleavage of a quenched fluorescent RNA to report activity. Increased
80 secondary structure decreased Cas13 activity across all three assay conditions (Fig. 1A). We
81 next quantified Cas13 activity by fitting the fluorescence curves to effectively first-order reaction
82 equations, defining activity as the rate of reporter cleavage (hr^{-1}), a proxy for the concentration
83 of active Cas13 in the system (see Methods). We observed a high degree of correlation
84 between the three types of target occlusion (Fig. 1B). Cas13 activity varied by an order of
85 magnitude for the same sequence with different amounts of target occlusion (Fig. 1C).

86 **Activity reduction is quantitatively explained by a kinetic strand** 87 **displacement model**

88 An equilibrium model based on the free energy of each target RNA (see Methods) failed to
89 quantitatively account for the degree of structure-mediated Cas13 activity reduction (Fig. 1C
90 light green dotted line). Labeling the free energy of the target-occluder complex by ΔG_u , the
91 disagreement between the large difference in thermodynamic drives ($\exp(-\beta\Delta G_u)$ ranges over
92 30 orders of magnitude) and the smaller difference in activities (ranging over 2 orders of
93 magnitude) cannot be explained by an equilibrium RNA-RNA hybridization framework. Given
94 known free energies of RNA-RNA binding²¹, the system temperature would have to be $\sim 7500\text{K}$
95 to match an equilibrium model to the measured Cas13 activity reduction.

96 We next sought to find a suitable alternative framework to explain the measured activity levels;
97 a strand displacement model presents one such framework²². In this model, after initial binding
98 to the target, the crRNA and occluding strand compete through a random-walk-like process until
99 either the occluding strand is fully displaced or the crRNA-Cas13 complex dissociates from the
100 target RNA^{23,24} (Fig. 1D). We hypothesized that strand displacement must occur for Cas13 to
101 bind structured RNA.

102 In our model, Cas13 first binds non-specifically to a region of RNA¹⁵ and then performs a local
103 search for a sequence complementary to its bound crRNA. If Cas13 is not activated within a
104 given time t_{dwell} (i.e. it does not fully bind to a protospacer sequence complementary to its
105 crRNA) it dissociates from the RNA and repeats the search process. This sequence of events is
106 analogous to the process by which enzymes such as the *E. coli lac* repressor search for their
107 binding site on DNA^{25,26}. However, the strand displacement model predicts that as secondary
108 structure length increases, the probability of Cas13 completing the strand displacement reaction
109 within the time t_{dwell} decreases, leading to a proportional decrease in Cas13 activity. This model
110 fits our measured results with a value of t_{dwell} equivalent to 100 steps of a strand displacement
111 reaction ($\sim 2 \times 10^{-5} \text{ s}$), in good agreement with direct measurements of typical dwell times for
112 DNA-binding proteins²⁵ (Fig. 1C dark green dotted line; see Methods).

113 **A massively multiplexed assay reveals structure effects are sequence** 114 **independent**

115 To probe the limits of the strand displacement model, we used a massively multiplexed assay to
116 explore a broad range of target structure conditions for multiple sequences. Our assay uses
117 DNA oligos to create secondary structure at defined positions in the target, having previously
118 validated their effect as a proxy for RNA structure (Fig. 1B, 2A). We designed a single 1kb-long
119 RNA molecule with minimal internal secondary structure²⁷ (Extended Data Fig. 1A-C); a
120 NUPACK prediction estimates its minimum free energy due to intramolecular contacts to be ~-6
121 kcal/mol, on par with random 35-nt-long RNA sequences²⁸. Our target RNA is divided into two
122 control blocks (one at each end of the molecule) and eight experimental blocks, allowing for
123 efficient multiplexing¹². Each block contains a 28-nt-long protospacer flanked by two 34-nt buffer
124 regions. For occlusion, we used DNA oligos of lengths 10, 14, 21, and 28 nucleotides (nt) in 3-
125 nt-spaced tilings, for a total of 4,608 simultaneous conditions. We tested these conditions in
126 parallel using a microfluidic chip-based assay⁶. Summaries of the resulting dataset are shown in
127 Fig. 2B and Extended Data Figs. 2 and 3.

128 Our results demonstrate that the reduction in Cas13 activity as a result of target structure is
129 relatively sequence-independent, with the 8 experimental target blocks showing similar activity
130 profiles in spite of large variation in absolute activity across these blocks (Fig. 2C, Extended
131 Data Fig. 2). While 10- and 14-nt-long occluders had negligible effects on Cas13 activity, 21-
132 and 28-mers had a strong effect. Consistent with earlier results, occluders binding to more of
133 the protospacer typically led to a greater activity reduction. In agreement with our dwell time
134 model and in contrast to other strand displacement systems^{24,29,30}, the presence or absence of
135 toeholds (unoccluded RNA) had little effect on Cas13 activity (Extended Data Figs. 4E-F).

136 The data also revealed an unexpected asymmetry among the effect of occluders on Cas13, in
137 which occluders binding to the 5' end of the protospacer had a larger effect on Cas13 activity
138 than occluders binding the same number of nucleotides at the 3' end (Fig. 2D, Extended Data
139 Fig. 4A-D). We accounted for the asymmetry in our model by adding a second parameter to the
140 model described above, creating a differential in t_{dwell} depending on whether or not the 5' end of
141 the protospacer is occluded. We found that our revised dwell time model was able to
142 quantitatively capture the effects of secondary structure on Cas13 activity (Fig. 2D, E).

143 **Structure occluding the region 3' of the protospacer inhibits Cas13**

144 Surprisingly, when occluders are placed directly 3' to the protospacer, Cas13 activity is potently
145 inhibited. This second regime of inhibition exists across all tested crRNAs, and inhibition is
146 strong for both 21mer and 28mer occluders (Fig. 2C). The non-monotonicity of this second
147 activity trough cannot be explained using a strand displacement model, implying this drop in
148 activity is not due to a reduction in crRNA-target binding.

149

150 We sought to probe whether this effect on Cas13 activity is a result of competitive or allosteric
151 inhibition. For the protospacer occluder, but not for the 3' occluder, we observe full rescue of
152 Cas13 activity when the crRNA and occluder are added at the same time. Increasing the

153 concentrations of 3' occluder does not increase their inhibitory effect (Fig. 2F). These results
154 indicate that the activity reduction conferred by occluding the region 3' to the protospacer is
155 likely the result of an allosteric effect.

156 **Strand displacement enhances mismatch detection**

157 We hypothesized that the insights from our strand displacement model could help us
158 dramatically improve the specificity of Cas13-based RNA detection assays. Past work has
159 shown that secondary structure can make nucleic acid hybridization more sensitive to
160 mismatches, both in CRISPR-based approaches and in other assays³¹⁻³⁴; we hypothesized that
161 given the kinetic nature of our assays, we could take advantage of the kinetic nature of strand
162 displacement to similar ends without the necessity of a binding toehold required in other
163 approaches. With no internal structure, even a mismatched crRNA is expected to bind strongly
164 to the target; however, an occluding strand provides an extra kinetic barrier that is less likely to
165 be overcome by a mismatched crRNA than by one that is perfectly complementary, thus
166 improving specificity given the short dwell time of inactive Cas13 on the RNA (Fig. 3A). A
167 differential-equation-based strand displacement model inspired by Ref.³⁵ supported this
168 hypothesis, revealing that even when both perfectly-complementary and mismatched invader
169 strands bind strongly to the target in equilibrium, in the presence of an occluding oligo, the
170 mismatched invader takes much longer to do so than the perfectly-matched invader (Fig. 3B).

171 We tested Cas13's ability to differentiate between a perfectly complementary target and one
172 containing a single A>U mutation at position 5 of the protospacer with and without secondary
173 structure occlusion. We tested both occluding the target (as we did previously) and occluding
174 the crRNA, reasoning that strand displacement would in either case result in improved
175 mismatch discrimination. The presence of a crRNA occluder resulted in a ~50x enhancement of
176 specificity compared to the no-occluder condition, measured as the maximum ratio of
177 WT/mismatch fluorescence (Fig. 3C). This effect was robust to large variations in concentration,
178 and was maximized at higher ~1-100 nM target input concentrations (Fig. 3D, Extended Data
179 Fig. 7B).

180 After testing target-occluding and crRNA-occluding oligos, and combinations of both (Fig. 3E,
181 Extended Data Fig. 5), we decided to focus on crRNA occluders. These provide the added
182 benefit of improving mismatch detection regardless of the identity of the mismatched target, and
183 they do not require any sample manipulation prior to detection.

184 We proceeded to explore the generality of Cas13 specificity enhancement by occluders. Using 3
185 different targets, 4 positions on each crRNA, and 2 mutations for each position, we tested how
186 well a mismatch could be detected by Cas13 with and without a crRNA-occluder. We measured
187 Cas13 activity on the perfectly matched and mismatched targets, finding that although only
188 74/96 mismatches (77%) led to any activity reduction in the absence of a crRNA-occluder, all 96
189 (100%) led to a reduction with the occluder (Fig. 4A-B, Extended Data Fig. 6). Error was thus
190 reduced from 23% to <1%. We found that without occlusion, the ability of Cas13 to distinguish
191 between a perfectly-matched target and a mismatched target is not guaranteed for any crRNA,
192 for any of the mismatch positions we tested, nor for any specific type of mutation (with the

193 exception of G>U, which has the fewest data points). However, using occluded crRNAs, Cas13
194 can distinguish perfectly-matched from mismatched targets in a position- and mutation-
195 independent manner.

196 We performed a dilution series of perfectly matched target RNA and mixed it with background
197 RNA containing a single mismatch. Without occlusion, the perfectly matched target was
198 detected at allele frequencies of 11% (a 1:8 ratio) but not 6% (1:16); with occlusion, it was
199 detected at frequencies as low as 0.4% (1:256) for all tested targets, an order-of-magnitude
200 sensitivity enhancement (Fig. 4C, Extended Data Fig. 7A).

201 To explore nucleotide-specific effects, we mutated the crRNA and target sequences to all
202 possible nucleotides at position 5 of the spacer. When testing all pairwise crRNA/target
203 combinations, we observed extensive cross-reactivity between crRNAs and targets in the
204 absence of occlusion. With occlusion, we observed specific detection of each target only by its
205 perfect-match crRNA (Fig. 4D, Extended Data Fig. 8). Occluded crRNAs can thus discriminate
206 all four possible alleles at a given position, demonstrating the exquisite specificity of the
207 approach.

208 To test the efficacy of our occlusion strategy in a real-world detection scenario, we designed
209 crRNAs targeting a single locus in the SARS-CoV-2 spike gene containing lineage-specific
210 mutations in adjacent codons. In this way, it is theoretically possible to distinguish Delta and
211 Omicron strains with only a single crRNA designed to identify each strain. Targeting
212 polymorphic sequences with conventional Cas13 detection schemes is challenging, as crRNAs
213 targeting a given mutation are likely to be affected by nearby mutations, making it nearly
214 impossible to distinguish variants from one another. We found that with crRNA occlusion, but
215 not in its absence, targeting this single locus leads to specific detection of the target strain in
216 both synthetic RNA (Fig. 4E, Extended Data Fig. 9) and amplified viral seedstocks (Fig. 4F)
217 using a simple fluorescence readout.

218 Discussion

219 In this study, we quantified the reduction in Cas13 activity due to target RNA occlusion, showed
220 that our results are quantitatively consistent with a strand-displacement-based model of Cas13
221 activation, and used this model to improve Cas13's mismatch specificity by an order of
222 magnitude.

223 Importantly, our method is simple to implement experimentally as it merely requires annealing a
224 DNA oligo to the crRNA prior to mixing with the target RNA. Unlike in other studies leveraging
225 RNA secondary structure to improve hybridization specificity, no toehold is required, enabling
226 trivial construction of the DNA oligo: all crRNA occluders used occluded the entire crRNA
227 spacer. The main downside of using crRNA-occluder duplexes to improve mismatch detection is
228 a reduction in Cas13 activity. To counteract this, steps can be taken to increase overall activity
229 such as increasing concentrations of Cas13, reporter, or target RNA.

230 While our experimental study focused on one ortholog of Cas13, LwaCas13a, our results are of
231 interest to many Cas13-based methods. Future work will explore to what extent the mechanism

232 of activation described here is generic or specific to this ortholog. Furthermore, significant
233 questions remain regarding the mechanism by which secondary structure 3' to the protospacer
234 leads to an allosteric reduction in Cas13 activity. For instance, extended complementarity
235 between the target and the structural portion of the crRNA (known as the tag-antitag effect)
236 inhibits Cas13 activity by preventing the proper formation of the active site^{36,37}. Future structural
237 and biochemical characterization will reveal whether the inhibitory region we have discovered
238 affects Cas13 by a similar or a different mechanism.

239 Due to its negligible cost, ease of implementation, orthogonality with existing approaches, and
240 marked improvement in detection specificity, we anticipate the adoption of our crRNA occlusion
241 approach into a wide range of Cas13-based techniques. Furthermore, our proposed strand
242 displacement model addresses a long-standing paradox, namely how a purportedly ssRNA-
243 specific enzyme is able to robustly target RNAs in cellular environments where RNA structure is
244 ubiquitous.

245 **Methods**

246 **General reagents**

247 Oligonucleotides were ordered from Integrated DNA Technologies (IDT). Unless otherwise
248 noted, chemical reagents were ordered from Sigma. Oligonucleotide sequences are listed in
249 Supplementary File 1.

250 **crRNA design**

251 Most crRNA spacers were designed to be perfectly complementary to their 28 nucleotide (nt)
252 protospacer region. For SARS-CoV-2 targeting sequences, a single synthetic mismatch was
253 inserted at position 5 to improve baseline specificity. Spacers were appended to the 3' end of
254 the consensus LwaCas13a direct repeat sequence
255 (AGACUACCCCAAAAACGAAGGGGACUAAAAC) and ordered from IDT as Alt-R guide RNA.

257 **Target design**

258 For our tiling experiment, we designed an RNA molecule of length 961 nucleotides with minimal
259 internal secondary structure. After an initial G nucleotide, the molecule is comprised of 10 target
260 blocks, each defined by a 34-nt buffer region, a 28-nt protospacer, and a second 34-nt buffer
261 region. We sought to have as many as possible of the 28-nt protospacers resemble natural
262 sequences.
263

264
265 To this end, we started with a set of 18,508 28-nt-long protospacer sequences compiled from
266 the ADAPT dataset, which has a sequence composition representative of viral diversity¹². 3,391
267 sequences with poly-A, poly-C, or poly-U stretches ≥ 5 nts or poly-G stretches ≥ 4 nts were
268 removed. Of the remaining sequences, we removed 6,459 which had low average measured
269 activity, defined as $\langle \text{out_log_k} \rangle \leq -2$ (on a logarithmic scale from -4 to 0, where 0 is high
270 activity) using the activity definitions and measurements from Ref¹². We used LandscapeFold³⁸
271 with parameter $m = 2$ (m represents the minimum allowed stem length), disallowing

272 pseudoknots, to predict the structure landscapes of the remaining sequences. LandscapeFold
273 predicted that 1,287 of these remaining sequences had extremely low intramolecular structure,
274 defined as all nucleotides having a $\geq 40\%$ probability of being unpaired in equilibrium.

275
276 We then aimed to find a set of these sequences that were all dissimilar from one another. First,
277 given a sequence s , we found all those sequences with a Hamming distance ≤ 15 from s . (A pair
278 of sequences with a Hamming distance of h share all but h nucleotides). Of these sequences,
279 we chose the one with the least secondary structure to keep and removed the others, with total
280 amount of secondary structure quantified as $\sum_n p_n$ where the sum is over nucleotides and p_n is
281 the probability of the nucleotide being paired in equilibrium. We repeated this step for each
282 sequence s we had not already removed. Next, we used a Smith-Waterman alignment³⁹ to
283 check for sequence similarity in non-identical nucleotide positions, repeating the same
284 procedure as above but, instead of Hamming distance, using the criteria of an alignment score
285 ≥ 9 to define sequence similarity, where the alignment score parameters were (+1, -2, -2) for
286 (match, mismatch, gap). This procedure resulted in a set of 20 sequences all distant from one
287 another in sequence space.

288
289 Finally, although we had ensured each of these sequences had low secondary structure, we
290 wanted to minimize binding between these sequences. For each pair of sequences, we used
291 LandscapeFold with parameter $m = 3$ to predict the structure of the two strands, allowing for
292 both intra- and inter-molecular interactions. We defined two sequences to be incompatible if the
293 resulting prediction had any nucleotide on either sequence with a $\leq 40\%$ probability of being
294 unpaired in equilibrium. We exhaustively enumerated the possible ordered sets of mutually
295 compatible sequences, finding 60 ordered sets of 5 mutually compatible sequences, and no set
296 of 6 mutually compatible sequences. Of these 60 sets, we chose the one with the least
297 structure. Under the assumption that entropic loop closure costs will create a barrier to non-
298 neighbor sequence pairing (i.e. that each sequence is less likely to pair to a sequence that isn't
299 its neighbor), we defined structure here as the sum, over the 4 pairs of neighboring sequences,
300 of the maximum probability of a nucleotide being paired in that sequence pair. Thus, we arrived
301 at a set of 5 distinct sequences from ADAPT with minimal intra- and inter-molecular structure.
302 These 5 sequences became the protospacer sequences corresponding to crRNAs 2, 4, 6, 8, 9.

303
304 The other 5 protospacer sequences as well as the buffer regions were compiled out of 64 16-nt-
305 long DNA sequences with minimal internal structure from Shortreed *et al.*²⁷. Seven of these
306 sequences with poly-A or poly-T stretches ≥ 5 nts were removed. Concatenating these
307 sequences resulted in a long sequence with minimal structure, which we used to construct the
308 rest of the 961 nt-long RNA target. We used NUPACK³⁴⁰ to predict the structure of the resulting
309 target, finding various predicted stems. We then made individual point mutations by hand in the
310 buffer regions and non-ADAPT-derived protospacers to minimize the probabilities of the
311 resulting stems (ensuring NUPACK predicted no base pair forming with probability $\geq 60\%$ in
312 equilibrium), as well as to remove sequence similarity between targets (ensuring there are no
313 more than 5 identical consecutive nucleotides between the protospacer regions, no more than 6
314 identical consecutive nucleotides between two regions spanning a protospacer and a buffer,
315 and no more than 8 identical consecutive nucleotides in buffer regions).

316
317 Finally, we created a “shuffled” version of the target, placing the target blocks (numbered 1 – 10
318 from 5’ to 3’ in the original target) in the following order: 1, 4, 2, 7, 5, 3, 9, 6, 8, 10. We ensured
319 NUPACK 3 did not predict any base pair forming with probability $\geq 60\%$ in the resulting
320 sequence.

321
322 For our initial experiments (Fig. 1) we filtered the ADAPT dataset sequences to those with high
323 activity ($\langle \text{out_log_k} \rangle > -2$) and perfect complementarity between target and crRNA in the ADAPT
324 dataset. We then measured LandscapeFold’s prediction of the secondary structure of each
325 candidate protospacer sequence. For each nucleotide, we calculated the total probability that
326 the nucleotide is unpaired in equilibrium. The protospacer chosen had each nucleotide with at
327 least a 92% probability of being unpaired in equilibrium.

328 329 **RNA preparation (including structured targets)**

330 RNA targets were ordered from Integrated DNA Technologies as DNA containing a T7 promoter
331 sequence. Targets were then transcribed to RNA using the T7 HiScribe High Yield RNA
332 Synthesis Kit in 55 μL reactions (New England Biolabs) with a 16h incubation step at 37 °C and
333 purified with 1.8X volume AMPure XP beads (Beckman Coulter) with the addition of 1.6X
334 isopropanol, then eluted into 20 μL of nuclease free (NF) water. All RNAs were then quantified
335 using a NanoDrop One (Thermo Fisher Scientific) or Biotek Take3Trio (Agilent) then stored in
336 nuclease free (NF) water at -80 °C for later use.

337
338 Occluded targets and crRNAs were prepared by mixing DNA/RNA oligo occluders with target
339 RNA or crRNA in 60mM KCl (Invitrogen) in NF water at a ratio of 2:1 (BioMark assays) or 10:1
340 (plate reader assays) and put through an annealing cycle consisting of a high-temperature
341 melting step at 85 °C for three minutes followed by gradual cooling to 10 °C at 0.1 °C/sec
342 followed by cooling to 4 °C. For massively multiplexed assays, occluders were first pooled by
343 length and start position within the target block (see Extended Data Fig. 1D) such that each
344 resulting oligo pool contained all 8 n-mers binding to a given position within each of the
345 experimental target blocks. Targets and crRNAs were then used for detection assays
346 immediately as described below.

347
348 Targets were input into detection reactions at various concentrations. For experiments in Fig. 1,
349 targets were input at 7.5×10^8 copies/ μL (cp/ μL). For experiments in Fig. 2a-e, targets were
350 input at 8×10^8 cp/ μL . For Fig. 2f, targets were input at 5×10^9 cp/ μL . For experiments in Fig. 3
351 and 4a-b, input concentrations of 7.5×10^9 cp/ μL were used unless otherwise noted in figure
352 caption. For Fig. 4c, targets were spiked in at the indicated allele frequency into a background of
353 5×10^{10} cp/ μL (for occluded conditions) or 5×10^8 cp/ μL (for non-occluded conditions). For Fig.
354 4d, occluded conditions used an input concentration of 5×10^{10} cp/ μL while non-occluded
355 conditions used a concentration of 5×10^8 cp/ μL .

356 357 **Viral seedstock amplification**

358 Extracted viral genomic RNA samples were acquired from BEI Resources (hCoV-19/USA/MD-
359 HP05285/2021 (B.1.617.2) Delta, hCoV-19/USA/GA-EHC-2811C/2021 (B.1.1.529) Omicron).

360 Amplification reactions using 2uL of viral RNA as the input (50uL total reaction volume) were
361 performed using the Qiagen One-Step RT-PCR kit according to the manufacturer's
362 specifications. The forward primer contained a T7 promoter sequence; 4uL of the RT-PCR
363 products were used as direct input for T7 transcription (see "RNA preparation" section above).
364

365 **Cas13 detection assays**


366 Standard bulk detection assays were performed by mixing target RNA at a ratio of 10% v/v with
367 90% Cas13 detection mix. The detection mix consisted of 1X RNA Detection Buffer (20 mM
368 HEPES pH 8.0, 54 mM KCl, 3.5% PEG-8000 in NF water), supplemented with 45nM purified
369 LwaCas13a (Genscript, stored in 100 mM Tris HCl pH 7.5 and 1 mM DTT), 1 U/μL murine
370 RNase Inhibitor (New England Biolabs), 62.5 nM fluorescent reporter
371 (/5FAM/rUrUrUrUrU/IABkFQ; IDT), 22.5 nM processed crRNA (IDT), and 14 mM MgOAc. In
372 experiments using crRNA occlusion, crRNAs were pre-annealed to DNA occluders as described
373 above, and used at a final concentration of 22.5 nM. 15 μL reactions were loaded in technical
374 triplicate onto a Greiner 384 well clear-bottom microplate (item no. 788096) and measured on
375 an Agilent BioTek Cytation 5 microplate reader for 3 hours with excitation at 485 nm and
376 detection at 528 nm every five minutes.
377

378 For tiling assays, Standard Biotools genotyping IFC (192.24 format) was used in a BioMark HD
379 for multiplexed detection. Assay mix (10% of final reaction volume) contained 1X Assay
380 Detection Mix (Standard Biotools) supplemented with 100 nM crRNA, 100 nM LwaCas13a
381 (Genscript, stored in 100 mM Tris HCl pH 7.5 and 1 mM DTT). Sample mix (90% of final
382 reaction volume) contained 1X Sample Buffer (44 mM Tris-HCl pH 7.5, 5.6 mM NaCl, 10 mM
383 MgCl, 1.1 mM DTT, 1.1% w/v PEG-8000), supplemented with murine RNase Inhibitor (1 U/μL,
384 NEB), fluorescent reporter (500 nM, IDT), 1x ROX reference dye (used for normalization of
385 random fluctuations in fluorescence between chambers) (Standard Biotools), 1X GE Buffer
386 (Standard Biotools), 20mM KCl, and occluded RNA target (9×10^8 cp/μL).
387

388 Sample volumes of 3.5μL and assay volumes of 3.5μL, in addition to appropriate volumes of
389 Control Line Fluid, Actuation Fluid, and Pressure Fluid (Standard Biotools), were loaded onto
390 192.24 genotyping IFC chip (Standard Biotools). Chips were then placed into the Fluidigm
391 Controller and loaded and mixed using the Load Mix 192.24 GE script (Standard Biotools).
392 After mixing, reactions were run on BioMark HD at 37°C for 8 hours with measurements taken in
393 the fluorescein amidite (FAM) and the carboxyrhodamine (ROX) channels every five minutes.
394 Normalized and background-subtracted fluorescence for a given time point was calculated as
395 $(FAM - FAM_background) / (ROX - ROX_background)$ where FAM_background and
396 ROX_background are the FAM and ROX background measurements.
397

398 **Activity fits**

399 Fluorescence curves were converted to activity scores by fitting the curves to effectively first-
400 order reactions. With a certain amount of active Cas13, the concentration of uncleaved reporter
401 is expected to decrease exponentially according to the reaction



402

403 where E^* is the concentration of active Cas13, U the concentration of uncleaved reporter, and P
404 the concentration of cleaved reporter RNA. Labeling the (second-order) rate constant of this
405 reaction as r , the concentration of P changes over time according to

$$406 \quad P(t) = P_{tot} - (P_{tot} - P(0))e^{-rEt}.$$

407 Assuming that E^* is constant over time, we define an activity score $\nu = rE^*$, which is an
408 effective first-order rate constant (with units of inverse time). Assuming that r is constant across
409 our assays, the activity score ν is thus a proxy for the amount of active Cas13. Given measured
410 $P(0)$, we find best-fit values of P_{tot} and ν to fit the kinetic curves. To account for curves very far
411 from saturation (e.g. NTC data) we set a minimum value of P_{tot} based on data from saturating
412 and near-saturating curves. For tiling data, we fit the first 50 timepoints (~4 hours) to discount
413 occasional apparent noise appearing at very late times.

414
415 Some assays including crRNA occluders displayed fluorescence curves that did not fit well to
416 this effective first-order reaction (Extended Data Figs. 5, 6, 7, 8) indicating a need to relax the
417 assumption that A is constant over time. For data shown in Extended Data Figs. 7A and 8, we
418 neglected the first several timepoints measured (15 and 10 timepoints, respectively,
419 corresponding to 75 and 50 min) since we found that doing so increased the goodness of fit. For
420 other assays using crRNA occluders—and those assays being directly compared to them (i.e.
421 those data shown in Extended Data Figs. 5, 6, 7B)—we fit the data to a series of two effective
422 first-order reactions:



424 Labeling the first-order rate constant of each reaction k_1 and k_2 , this model yields

$$425 \quad P(t) = P_{tot} - (P_{tot} - P(0)) \frac{k_1 e^{-k_2 t} - k_2 e^{-k_1 t}}{k_1 - k_2}.$$

426 We define activity in this case as $\nu = (1/k_1 + 1/k_2)^{-1}$, verifying that if the equation is first order
427 (i.e. $k_1 \gg k_2$), our previous definition of activity is recovered. We indeed find negligible change in
428 the measured activities for no-occluder control (NOC) fluorescence curves between these two
429 fits.

430

431 **Tiling experiment activity correction**

432 Each experimental condition in the tiling experiment was performed with four replicates: two
433 technical replicates for each of the two “shuffles” of the 961-nt-long target sequence. While we
434 found excellent agreement between technical replicates (Extended Data Fig. 3B), there was
435 some variation between the results from each of the two target “shuffles” (Extended Data Fig.
436 3H). This variation was apparent in and correlated between the positive controls of crRNAs 1
437 and 10, which were always unoccluded (Extended Data Fig. 3C, H). We hypothesized that this
438 variability results from small variations in target concentration in our different samples.

439

440 To correct for such variations, we sought to quantify how much each RNA sample differed from
441 the mean. The RNA samples were divided into 192 sample conditions, each corresponding to a
442 single oligo pool and one target shuffling (see “RNA preparation” section, Extended Data Fig.
443 1C). Each of these 192 conditions was mixed with 24 assay conditions, corresponding to 8
444 experimental crRNAs, 2 positive control crRNAs, one non-targeting crRNA, one no-crRNA
445 control (NPC) and two replicates of each.

446

447 For the two replicates of crRNAs 1 and 10 (i.e. for each of the 4 positive control assay
448 conditions out of the 24 total assays), we considered the activity fit from the mean fluorescence
449 curve, averaging over the 192 sample conditions (Extended Data Fig. 3B, black dashed lines).
450 Then, for each sample condition, and for each positive control, we calculated the ratio of the
451 control's activity to its mean activity across all samples, obtaining an estimate of the degree to
452 which that sample's concentration deviated from the mean. We defined a correction factor as
453 the average of these ratios. We then divided all activities measured for that sample by this
454 correction. This activity correction not only decreased the spread of activities measured by the
455 positive controls (Extended Data Fig. 3D-G) but also decreased the variance between
456 measurements made on the two target "shuffles" (Extended Data Fig. 3H).

457

458 **Mismatch discrimination**

459 In Fig. 3D we show the results of one simple metric by which to measure mismatch
460 discrimination: the maximum of the ratio F_{PM} / F_{MM} , where F_{PM} is the average fluorescence
461 measurement across the perfectly matched conditions, and F_{MM} across the mismatched
462 conditions. To account for the arbitrary offset of fluorescence, the minimum fluorescence
463 measured across the NTC experiments was subtracted from both F_{PM} and F_{MM} before taking the
464 ratio. Since F_{PM} and F_{MM} are each measured as the average across three replicates, each
465 measurement of F_{PM} and F_{MM} has an inherent error, σ_{PM} and σ_{MM} (respectively), which we
466 quantify as the standard deviation across the three replicates at each timepoint. The error of the
467 ratio is then propagated as

468

$$\frac{\sqrt{(F_{PM}\sigma_{MM})^2 + (F_{MM}\sigma_{PM})^2}}{(F_{MM})^2}.$$

469


470 Elsewhere (Fig. 3E, Figs. 4A, B) we measure mismatch discrimination by a metric that relies on
471 activity fits: $\log_2(v_{PM} / v_{MM})$. Thus, a mismatch discrimination of 1 indicates that the measured
472 activity of the perfectly matched conditions is twice that of the mismatched conditions, and a
473 discrimination of 3 indicates the perfectly matched conditions had eight-fold higher activity than
474 the mismatched conditions. We used a similar measure for discrimination at low allele
475 frequencies (Fig. 4C), defining activity discrimination as $\log_2(v_f / v_0)$ where v_f is the activity
476 measured at allele frequency f , and v_0 the activity measured in the background alone.

477

478 **Equilibrium model**

479 In an equilibrium model of crRNA-target hybridization, the target has a free energy ΔG_u that
480 depends on occluder conditions, and the crRNA-target complex has free energy independent of
481 occluder. A kinetic model describing crRNA-target hybridization would be

482



483 with the ratio of forward to reverse rate constants determined by the free energy difference
484 between the target-unbound and target-bound states. Assuming that the target is in excess, we
485 define an unknown parameter α_1 such that at steady state,

486

$$E^* = \frac{E_{tot}}{1 + e^{-\beta(\Delta G_u - \alpha_1)}}$$

487 where $\beta = 1 / k_B T$, with k_B denoting Boltzmann's constant and T temperature (measured in
488 Kelvin), and $E_{\text{tot}} = E + E^*$ is the total concentration of Cas13 enzyme in the system (measured in
489 Molar).

490

491 Our measured activity, ν , is proportional to E^* as defined previously: $\nu = rE^*$. Considering ν on a
492 logarithmic scale (as it is plotted in Fig. 1C) yields

493
$$\log(\nu) - \alpha_2 = -\log(1 + e^{-\beta(\Delta G_u - \alpha_1)})$$

494 with $\alpha_2 = \log(rE_{\text{tot}})$.

495

496 The two parameters α_1 and α_2 therefore only shift the curve relating $\log(\nu)$ to ΔG_u , but cannot
497 alter the shape of the curve itself.

498

499 That the relationship between $\log(\nu)$ and ΔG_u is approximately linear can be seen by
500 recognizing that if

501
$$e^{-\beta(\Delta G_u - \alpha_1)} \gg 1,$$

502 as is typical in our system, we have

503
$$\log(\nu) \approx \beta \Delta G_u - (\alpha_1 - \alpha_2),$$

504 indicating that there is in essence only one free parameter in the system that shifts the line but
505 cannot change its slope. The slope is set by the temperature of the system.

506

507 **ODE model**

508 We compared the binding rate of an invading strand to a target with and without an occluder in a
509 model based on Srinivas & Oulridge *et al.* (2013) and Irmisch *et al.* (2020)^{29,35}. The model
510 consists of a set of ordinary differential equations (ODEs) representing the flux into and out of
511 states, where each state is defined by the set of base pairs formed. Transitions between states
512 occur at a rate $ke^{-\Delta G}$ where ΔG is the free energy barrier to the transition (in units of $k_B T$ where
513 k_B is Boltzmann's constant and T is temperature in units of Kelvin) and k is an overall rate
514 constant. An initial state consists of a target strand (bound to an occluding strand in the case
515 where an occluding strand is considered), with an invading strand unbound. Initial binding of the
516 invader strand to the toehold has a free energy barrier of ΔG_a . The reverse step has a barrier of
517 $h\Delta G_R$ where h is the toehold length and ΔG_a is the (absolute value of the) typical free energy of
518 an RNA-RNA base pair.

519

520 In the no-occluder case, subsequent forward steps (in which an additional base pair between
521 target and invader forms) have a free energy barrier of 0, while reverse steps have a free
522 energy barrier of ΔG_a .

523

524 In the occluder case, the first step of the strand displacement reaction has barrier $\Delta G_P + \Delta G_S -$
525 $(\Delta G_R - \Delta G_D)$, where we have subtracted $(\Delta G_R - \Delta G_D)$ from the models on which we base our
526 work to account for the fact that in our system, the invading strand is RNA while the occluding
527 strand is DNA; ΔG_D is the (absolute value of the) typical free energy of an RNA-DNA base pair.
528 Subsequent forward steps in the strand displacement reaction have a barrier of $\Delta G_S - (\Delta G_R -$

529 ΔG_D), while backward steps all have a barrier of ΔG_S . The barrier from the final state, in which
530 the occluder has fully dissociated, back to the penultimate state, has a barrier of ΔG_D .

531
532 Parameters were set following Irmisch *et al.* to: $\Delta G_a = 18.6$; $\Delta G_R = 2.52$; $\Delta G_S = 7.4$; $\Delta G_p = 3.5$;
533 $\Delta G_m = 9.5$ (all in units of $k_B T$); and an overall rate constant of $k = 6 \times 10^7/s$. We set $\Delta G_D = 1.2$ to
534 be roughly half of ΔG_R , and $\Delta G_D = 25$ to be large enough to prevent reassociation on the
535 timescales considered. In Fig. 3C we plot the results of $h = 3$, $b = 27$, with a mutation at the first
536 position after the toehold.

537

538 **Strand displacement model**

539 In the strand displacement model, non-specific binding of Cas13 to the RNA (independent of
540 RNA sequence) leads to Cas13 activation, and a corresponding decrease in Cas13 dissociation
541 rate, when the crRNA fully binds to the protospacer complement. We denote the typical dwell
542 time of Cas13 on the RNA in the absence of this activation by t_{dwell} , the main parameter in the
543 model. Secondary structure affects activity by modulating the probability that a strand
544 displacement reaction completes within this time t_{dwell} . We assume that activity is directly
545 proportional to this probability. To estimate this probability, for each occluder, we simulated 10^5
546 unbiased random walks of length equal to the number of occluded protospacer nucleotides with
547 a reflecting boundary at 0, measuring the number of steps taken to complete the random walk,
548 and therefore the probability of completing the random walk within a desired number of steps.
549 The number of trials chosen leads to errors in our estimate of this probability $< 3\%$ in all cases
550 (determined by the maximum ratio of standard deviation to the mean of our estimate across 10
551 replicates of 10^5 random walks).

552

553 To estimate a typical value of t_{dwell} , we turn to classic studies of the *E. coli lac* repressor, a DNA-
554 binding enzyme which searches for its binding site on the DNA by iteratively binding non-
555 specifically to the DNA, performing a local search, and dissociating^{25,26}. The dissociation rate of
556 the *lac* repressor when non-specifically binding DNA (i.e. the inverse of its dwell time) has been
557 estimated²⁵ to be $5 \times 10^4/s$. This dwell time corresponds to the time it would take for ~ 100 steps
558 of a strand displacement reaction, where the rate of individual steps has been estimated³⁵ to be
559 $6 \times 10^7 \times e^{-2.5}/s \approx 5 \times 10^6/s$. This dwell time varies with ionic concentration (among other
560 factors), with dwell time decreasing anywhere from 2-10-fold upon doubling KCl concentration²⁵.
561 Given the different conditions used in the plate-reader assays and in the tiling experiments,
562 including different ionic conditions—with the former having ~ 2.5 -fold higher KCl concentrations
563 than the latter—we fit t_{dwell} separately for the two experimental methods. We used a dwell time
564 of 100 steps of a strand displacement reaction for the plate-reader assays, and a dwell time of
565 300 steps for the tiling experiments.

566

567 To account for the asymmetry seen in our data (Fig. 2D, Extended Data Fig. 4A-D) we allowed
568 for dwell time to change depending on whether the 5' end of the protospacer was occluded or
569 unoccluded. For the plate reader assays, our final model has a dwell time of 100 steps for those
570 cases where the 5' end of the protospacer was occluded, and a dwell time of 200 steps for
571 those cases where it wasn't. For the tiling assays, the dwell times used are 300 and 600 steps,
572 respectively.

573 References

- 574 1. Schertzer, M. D. *et al.* Cas13d-mediated isoform-specific RNA knockdown with a unified
575 computational and experimental toolbox. *bioRxiv* (2023) doi:10.1101/2023.09.12.557474.
- 576 2. Abudayyeh, O. O. *et al.* RNA targeting with CRISPR-Cas13. *Nature* **550**, 280–284 (2017).
- 577 3. Gootenberg, J. S. *et al.* Nucleic acid detection with CRISPR-Cas13a/C2c2. *Science* **356**,
578 438–442 (2017).
- 579 4. Cox, D. B. T. *et al.* RNA editing with CRISPR-Cas13. *Science* **358**, 1019–1027 (2017).
- 580 5. Wang, H. *et al.* CRISPR-mediated live imaging of genome editing and transcription.
581 *Science* **365**, 1301–1305 (2019).
- 582 6. Welch, N. L. *et al.* Multiplexed CRISPR-based microfluidic platform for clinical testing of
583 respiratory viruses and identification of SARS-CoV-2 variants. *Nat. Med.* **28**, 1083–1094
584 (2022).
- 585 7. East-Seletsky, A. *et al.* Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA
586 processing and RNA detection. *Nature* **538**, 270–273 (2016).
- 587 8. Meeske, A. J., Nakandakari-Higa, S. & Marraffini, L. A. Cas13-induced cellular dormancy
588 prevents the rise of CRISPR-resistant bacteriophage. *Nature* **570**, 241–245 (2019).
- 589 9. Liu, L. *et al.* The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a. *Cell*
590 **170**, 714–726.e10 (2017).
- 591 10. Yang, L.-Z. *et al.* Dynamic Imaging of RNA in Living Cells by CRISPR-Cas13 Systems. *Mol.*
592 *Cell* **76**, 981–997.e7 (2019).
- 593 11. Abudayyeh, O. O. *et al.* C2c2 is a single-component programmable RNA-guided RNA-
594 targeting CRISPR effector. *Science* **353**, (2016).
- 595 12. Metsky, H. C. *et al.* Designing sensitive viral diagnostics with machine learning. *Nat.*
596 *Biotechnol.* **40**, (2022).
- 597 13. Wei, J. *et al.* Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA

- 598 targeting. *bioRxiv* 2021.09.14.460134 (2023) doi:10.1101/2021.09.14.460134.
- 599 14. Wessels, H.-H. *et al.* Prediction of on-target and off-target activity of CRISPR-Cas13d guide
600 RNAs using deep learning. *Nat. Biotechnol.* (2023) doi:10.1038/s41587-023-01830-8.
- 601 15. Smargon, A. A. *et al.* Cas13b Is a Type VI-B CRISPR-Associated RNA-Guided RNase
602 Differentially Regulated by Accessory Proteins Csx27 and Csx28. *Mol. Cell* **65**, 618–630.e7
603 (2017).
- 604 16. Mantena, S. *et al.* Model-directed generation of CRISPR-Cas13a guide RNAs designs
605 artificial sequences that improve nucleic acid detection. *bioRxiv* 2023.09.20.557569 (2023)
606 doi:10.1101/2023.09.20.557569.
- 607 17. Tambe, A., East-Seletsky, A., Knott, G. J., Doudna, J. A. & O’Connell, M. R. RNA Binding
608 and HEPN-Nuclease Activation Are Decoupled in CRISPR-Cas13a. *Cell Rep.* **24**, 1025–
609 1036 (2018).
- 610 18. Vargas, A. M. M. *et al.* New design strategies for ultra-specific CRISPR-Cas13a-based
611 RNA-diagnostic tools with single-nucleotide mismatch sensitivity. *bioRxiv* (2023)
612 doi:10.1101/2023.07.26.550755.
- 613 19. Kuo, H.-C., Prupes, J., Chou, C.-W. & Finkelstein, I. J. Massively Parallel Profiling of RNA-
614 targeting CRISPR-Cas13d. *bioRxiv* (2023) doi:10.1101/2023.03.27.534188.
- 615 20. Bandaru, S. *et al.* Structure-based design of gRNA for Cas13. *Sci. Rep.* **10**, 1–12 (2020).
- 616 21. Turner, D. H. & Mathews, D. H. NNDB: The nearest neighbor parameter database for
617 predicting stability of nucleic acid secondary structure. *Nucleic Acids Res.* **38**, 2009–2011
618 (2009).
- 619 22. Simmel, F. C., Yurke, B. & Singh, H. R. Principles and Applications of Nucleic Acid Strand
620 Displacement Reactions. *Chem. Rev.* **119**, 6326–6369 (2019).
- 621 23. Radding, C. M., Beattie, K. L., Holloman, W. K. & Wiegand, R. C. Uptake of homologous
622 single-stranded fragments by superhelical DNA. IV. Branch migration. *J. Mol. Biol.* **116**,
623 825–839 (1977).

- 624 24. Zhang, D. Y. & Winfree, E. Control of DNA Strand Displacement Kinetics Using Toehold
625 Exchange. *J. Am. Chem. Soc.* **131**, 1–16 (2009).
- 626 25. Winter, R. B., Berg, O. G. & von Hippel, P. H. Diffusion-driven mechanisms of protein
627 translocation on nucleic acids. 3. The Escherichia coli lac repressor--operator interaction:
628 kinetic measurements and conclusions. *Biochemistry* **20**, 6961–6977 (1981).
- 629 26. Halford, S. E. & Marko, J. F. How do site-specific DNA-binding proteins find their targets?
630 *Nucleic Acids Res.* **32**, 3040–3052 (2004).
- 631 27. Shortreed, M. R. *et al.* A thermodynamic approach to designing structure-free combinatorial
632 DNA word sets. *Nucleic Acids Res.* **33**, 4965–4977 (2005).
- 633 28. Fornace, M. E. *et al.* NUPACK: Analysis and Design of Nucleic Acid Structures, Devices,
634 and Systems. *ChemRxiv* (2022) doi:10.26434/chemrxiv-2022-xv98l.
- 635 29. Srinivas, N. *et al.* On the biophysics and kinetics of toehold-mediated DNA strand
636 displacement. *Nucleic Acids Res.* **41**, 10641–10658 (2013).
- 637 30. Yurke, B. Using DNA to power nanostructures. *Genet. Program. Evolvable Mach.* **4**, 111–
638 122 (2003).
- 639 31. Zhang, D. Y., Chen, S. X. & Yin, P. Optimizing the specificity of nucleic acid hybridization.
640 *Nat. Chem.* **4**, 208–214 (2012).
- 641 32. Kocak, D. D. *et al.* Increasing the specificity of CRISPR systems with engineered RNA
642 secondary structures. *Nat. Biotechnol.* **37**, 657–666 (2019).
- 643 33. Haley, N. E. C. *et al.* Design of hidden thermodynamic driving for non-equilibrium systems
644 via mismatch elimination during DNA strand displacement. *Nat. Commun.* **11**, (2020).
- 645 34. Wu, Y. *et al.* A PAM-free CRISPR/Cas12a ultra-specific activation mode based on toehold-
646 mediated strand displacement and branch migration. *Nucleic Acids Res.* **50**, 11727–11737
647 (2022).
- 648 35. Irmisch, P., Ouldridge, T. E. & Seidel, R. Modeling DNA-Strand Displacement Reactions in
649 the Presence of Base-Pair Mismatches. *J. Am. Chem. Soc.* **142**, 11451–11463 (2020).

- 650 36. Meeske, A. J. & Marraffini, L. A. RNA Guide Complementarity Prevents Self-Targeting in
651 Type VI CRISPR Systems. *Mol. Cell* **71**, 791–801.e3 (2018).
- 652 37. Wang, B. *et al.* Structural basis for self-cleavage prevention by tag:anti-tag pairing
653 complementarity in type VI Cas13 CRISPR systems. *Mol. Cell* **81**, 1100–1115.e5 (2021).
- 654 38. Kimchi, O., Cragolini, T., Brenner, M. P. & Colwell, L. J. A Polymer Physics Framework for
655 the Entropy of Arbitrary Pseudoknots. *Biophys. J.* **117**, 520–532 (2019).
- 656 39. Smith, T. F. & Waterman, M. S. Identification of common molecular subsequences. *J. Mol.*
657 *Biol.* **147**, 195–197 (1981).
- 658 40. Zadeh, J. N. *et al.* NUPACK: Analysis and Design of Nucleic Acid Systems. *J. Comput.*
659 *Chem.* **32**, 170–173 (2010).

660 **Acknowledgments**

661 We thank Brian Kang, Britt Adamson, Rees Garmann, and Herman Dhaliwal, as well as the
662 members of the Myhrvold and te Velthuis labs, for useful discussions.

663 **Author contributions**

664 All authors (O.K., B.B.L., O.R.S.D., A.J.W.t.V., C.M) designed research. B.B.L. and O.R.S.D.
665 performed experiments. O.K., B.B.L., O.R.S.D., and C.M. performed data analysis. O.K. and
666 C.M. performed modeling. All authors (O.K., B.B.L., O.R.S.D., A.J.W.t.V., C.M) wrote the article.

667 **Competing interests**

668 C.M. is a co-founder and consultant to Carver Biosciences and holds equity in the company. All
669 authors (O.K., B.B.L., O.R.S.D., A.J.W.t.V., C.M) are co-inventors on a patent application
670 relating to this study.


671

672 **Funding**

673 The authors and research reported in this manuscript were supported by the National Institutes
674 of Health grant DP2 AI175474-01 (to A.J.W.t.V.); National Institutes of Health grant R21
675 AI168808-01, Centers for Disease Control and Prevention grant 75D30122C15113, and the
676 Princeton Catalysis Initiative (all to C.M.); the Peter B. Lewis '55 Lewis-Sigler Institute/Genomics
677 Fund through the Lewis-Sigler Institute of Integrative Genomics at Princeton University, and the
678 National Science Foundation through the Center for the Physics of Biological Function (PHY-

679 1734030) (O.K.). B.B.L. was supported by National Institutes of Health grants T32GM007388
680 and T32GM148739.


681 Figures



682


683 **Fig. 1: RNA structure leads to a reduction in Cas13 activity due to strand displacement.**

684 **A:** Different amounts of structure were introduced into the target via intramolecular structure,
 685 RNA oligos, and DNA oligos; resulting fluorescent kinetic curves. Target input concentration: 7.5
 686 $\times 10^8$ copies/ μL . “Mut” denotes 28nt of occlusion with nine mismatches to weaken binding. Data
 687 from $n=3$ technical replicates are shown (dots). **B:** Scatter plot comparing the impact of the
 688 different occlusion types depicted in (A) on Cas13 activity; x axis: Cas13 activity when occluded
 689 by DNA oligos, y axis: Cas13 activity when occluded by intramolecular RNA or RNA oligos. **C:**
 690 Cas13 activity vs. occluder length for RNA occluders is compared to two single-parameter
 691 models: an equilibrium model based on crRNA-target hybridization free energies (pink) and a
 692 free-energy-independent strand displacement model (green). Effects of changing the single
 693 parameter are indicated by arrows. Gray bar is NTC. **D:** Overview of strand displacement
 694 reactions. After initial binding to part of the target (blue), the crRNA (pink) and occluder (red)
 695 undergo a random walk process until one or the other is fully displaced. Displacement of the
 696 occluder leads to Cas13 activation. Error bars in B and C show standard deviation.



697


698 **Fig. 2: A massively multiplexed assay modulating secondary structure.** **A:** Overview of the
 699 multiplexed assay, in which a total of 4,608 simultaneous assays were performed, with oligo
 700 occluders of lengths 10, 14, 21, 28 tiling each protospacer region in 3-nt increments. Made
 701 using BioRender. **B:** Overview of the Cas13 activity data from the multiplexed assay. Each data
 702 point represents the mean activity resulting from averaging four time series curves (see
 703 Methods), normalized to the non-occluded condition; positive and negative controls are not
 704 shown (Extended Data Fig 3). **C:** Heat map showing the degree of activity reduction (darker
 705 greens) by each 21mer and 28mer occluder. **D:** Cumulative histogram of inhibition asymmetry,
 706 defined as the ratio of activities when the same numbers of nucleotides are occluded at the 3'
 707 vs. 5' ends of the protospacer (see Extended Data Fig. 4C,D). **E:** Normalized Cas13 activity for
 708 21mer (green) and 28mer (purple) occluders with different start positions in the region around
 709 the protospacer. Each line represents one crRNA. **F:** Bar chart showing the inhibitory effect of
 710 28mer occluders overlapping the protospacer or the region 3' to the protospacer, at different
 711 occluder concentrations and when annealing the occluder before or at the same time as the
 712 crRNA. In E and F, error bars show standard deviation.



713

714 **Fig. 3: Designed secondary structure enhances Cas13 mismatch detection.** **A:** Schematic
 715 showing strand displacement by Cas13 with a perfectly-matched target sequence versus one
 716 containing a mismatch. **B:** ODE-based model predictions of crRNA/target hybridization kinetics
 717 with and without occlusion and mismatches. **C:** Kinetic curves showing detection of a target
 718 sequence with and without a single A>U mismatch at spacer position 5, in the presence and
 719 absence of occlusion. Shaded region shows range of fluorescence measurements for each
 720 condition across replicates. **D:** Maximum fluorescence ratios with and without occlusion at a
 721 variety of target input concentrations (see Methods). **E:** Mismatch discrimination, defined as
 722 $\log_2(\text{perfect match activity} / \text{mismatch activity})$, for two single mutations and one double mutation
 723 using occluders blocking either the target, the crRNA, or both. Error bars in D and E show
 724 standard deviations propagated through the relevant formulae (see Methods).

725




726

727 **Fig. 4: crRNA ocluders enable consistent and sensitive mismatch discrimination. A:**
 728 Violin plots showing the ability of Cas13 to distinguish between wildtype targets and targets
 729 containing mutations at four different positions in the protospacer both with and without
 730 occlusion; position is relative to the 5' end of the protospacer. Each data point is the
 731 discrimination ratio of perfect-match to mismatched sequence (defined as in Fig. 3E; see
 732 Methods). **B:** Data from A, but organized by mutation type. **C:** Heatmap showing the ability of
 733 Cas13 to detect spiked-in target in a background of mismatched sequence at decreasing allele
 734 frequencies, both with and without occlusion. Asterisks indicate statistically significant detection
 735 over the no-spike in control. Significance determined by one-tailed t-test $p < 0.05$. Activity
 736 discrimination is defined analogously to mismatch discrimination (see Methods). **D:** Specificity
 737 matrix showing Cas13 activity normalized for each target, with and without occlusion, for all
 738 possible crRNA and target nucleotides at position 5. **E:** Detection of synthetic Delta and
 739 Omicron SARS-CoV-2 Spike gene RNA with crRNAs specific to Delta or Omicron using total
 740 fluorescence after 90 minutes. Fluorescence of each target was normalized independently after
 741 subtracting minimum NTC at 90 minutes. **F:** Same as in E, but using amplified viral seedstocks.


742 Extended data figures

743




744

745 **Extended Data Fig. 1: Multiplexing RNA secondary structure for Cas13-based assays. A.**
 746 Criteria used in the design of target RNAs for multiplexed detection assays. **B.** Histogram
 747 showing the minimum and total structure free energies of randomly generated RNA sequences,
 748 compared to the free energy of the two target RNAs used in the tiling experiment. **C.** NUPACK 3
 749 predicted minimum free energy structures for the two experimental targets⁴⁰. **D.** Overview of the
 750 multiplexed tiling experiment. Made using BioRender.



751


752 **Extended Data Fig. 2: Activity profiles of Cas13 targeting occluded RNAs. A-D.** Cas13
 753 activity as a function of occluder start position in each 96 nt target block. **A:** 28-mers. **B:** 21-
 754 mers. **C:** 14-mers. **D:** 10-mers. **E-H.** Same as A-D, with activities normalized to the non-
 755 occluded condition for each target block **I.** Activities of all negative control conditions. **J.**
 756 Normalized activities as a function of occluder start position for a single target with all four
 757 occlusion lengths.



758


759 **Extended Data Fig. 3: Controls and data normalization for multiplexed tiling assay. A.**

760 Fluorescence curves for the set of experimental conditions chosen for the multiplexed tiling
 761 assay. **B.** Scatter plot showing activity correlation between technical replicates in the tiling
 762 experiment. **C.** Raw activity curves from the control (unoccluded) targets across all conditions in
 763 tiling assay. **D.** Swarm plot showing control target activities before and after correction. **E.**
 764 Cumulative histogram showing activity distribution for control target 1 before and after
 765 correction. **F.** Same as in E, but for control target 10. **G.** Dot plot showing activity correlations
 766 between the two control targets for all conditions before and after correction. **H.** Scatter plot
 767 showing activity correlation between the two target shufflings for all tested conditions, before
 768 and after correction. Inset: histogram of ratio of activities of points of the two target shufflings,
 769 before and after correction, excluding negative controls. In E, F, H (inset), σ represents standard
 770 deviation.




771

772 **Extended Data Fig. 4: Strand displacement-based t_{dwell} model accounts for asymmetries**
 773 **in occlusion pattern. A.** Activity as a function of DNA occluder length for occluders of different
 774 lengths extending inwards from 3' and 5' ends of the protospacer. Strand displacement model
 775 predictions shown as dashed lines. **B.** Data from tiling experiment plotted as in A and also
 776 including oligos occluding the middle of the protospacer (yellow). Small dots show individual
 777 data points from each crRNA; large dots show the mean; error bars show standard deviation.
 778 Model predictions shown as dashed lines. **C.** Ratio of activities resulting from 21-mer occluders
 779 targeting 3' end of protospacer to those resulting from occluders targeting 5' end, plotted as a
 780 function of occluder length. Each curve shows a different crRNA. Model prediction shown as
 781 dashed line. Cumulative histograms of these data are shown in Fig. 2D. **D.** As in C, for 28-mer
 782 occluders. **E-F.** Correlation between activities resulting from 21-mer occluders and 28-mers
 783 occluding the same nucleotides. In E, 28-mers starting at positions 1, 4, 7, etc are matched with
 784 21-mers starting at positions 3, 6, 9, etc; in F they are matched with 21-mers starting at
 785 positions 6, 9, 12, etc.



786


787 **Extended Data Fig. 5: Occlusion of target RNA and crRNA increase Cas13's sensitivity to**
 788 **mismatches.** Note on occluder nomenclature: occluders are named according to their start
 789 position from the 5' end of the target block; all occluders here are 28nt in length. Occluder s19
 790 binds to nucleotides 1-13 of the protospacer and extends into the 5' flanking region, s31 binds to
 791 nucleotides 1-25 and extends slightly into the 5' flanking region, s52 binds to nucleotides 18-28
 792 and extends into the 3' flanking region, and s61 binds to nucleotide 28 of the protospacer and
 793 extends into the 3' flanking region. **A.** Bar charts corresponding to Fig. 3E, representing Cas13
 794 activity for perfectly-matched and mismatched targets when occluded by several different target-
 795 blocking occluders, as well as crRNA occluders and combinations thereof. Upper dotted line
 796 indicates activity saturation point; curves above saturation are not fit well by exponentials and
 797 therefore bars in this region are not accurate measurements of activity. **B.** NTC (no-target
 798 control) raw curves for conditions with and without a crRNA occluder. **C.** Raw fluorescence
 799 curves and fits for the data shown in A.



800


801 **Extended Data Fig. 6: Mismatch detection using different types of occlusion.** Raw
 802 fluorescence curves corresponding to Fig. 4A-B detecting various mismatches within three
 803 different target sequences for no occlusion, target occlusion, crRNA occlusion, and
 804 target+crRNA occlusion conditions.

805




806

807 **Extended Data Fig. 7: Fluorescence curves from experiments probing Cas13 mismatch**
 808 **detection at low allele frequencies and varying target concentration with occlusion. A.**
 809 Raw fluorescence curves corresponding to Fig. 4C detecting mismatch detection sensitivity at
 810 decreasing allele frequency with and without occlusion. **B.** Raw fluorescence curves
 811 corresponding to Fig. 3D detecting presence of a mismatch at different target RNA
 812 concentrations with and without occlusion. Shaded regions show the range of fluorescence
 813 measurements for each condition across replicates.



814

815 **Extended Data Fig. 8: Fluorescence curves from Cas13 specificity matrix experiment with**
 816 **different types of occlusion.** Raw fluorescence curves corresponding to Fig. 4D using all
 817 possible crRNA and target nucleotides at a given position. Semi-transparent dashed lines show
 818 curve fits (see Methods).



819

820 **Extended Data Fig. 9: Fluorescence curves for SARS-CoV-2 variant calling experiments.**

821 Raw fluorescence curves corresponding to Figs. 4E and F targeting both Delta and Omicron

822 variants with guides specific to each variant.